依达拉奉
肌萎缩侧索硬化
利鲁唑
药品
生物
药理学
疾病
多发性硬化
医学
免疫学
内科学
出处
期刊:Cell
[Elsevier]
日期:2017-11-01
卷期号:171 (4): 725-725
被引量:134
标识
DOI:10.1016/j.cell.2017.10.011
摘要
Amyotrophic lateral sclerosis (ALS) is a progressive, adult onset neurodegenerative disease that is always fatal. The history of ALS drug discovery is fraught with many stops and starts. It took 22 years after the FDA approval of the anti-excitotoxic drug Riluzole before another drug was found to be effective in altering ALS progression: the anti-oxidant Edaravone.
科研通智能强力驱动
Strongly Powered by AbleSci AI